Qiming Weekly | Qiming Venture Partners Portfolio Companies Funding and Updates Vol. 23, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
Every step entrepreneurs take amid the waves of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
IPO
Pioneer in China's AI Technology Commercialization
Unisound Successfully Lists on the Hong Kong Stock Exchange
On June 30 Beijing time, Qiming Venture Partners portfolio company and pioneer in China's AI technology commercialization, Unisound, successfully listed on the Hong Kong Stock Exchange. Unisound (09678.HK) priced its IPO at HK$205.00 per share, giving it a market capitalization of HK$14.545 billion.
Qiming Venture Partners has been with Unisound for over a decade. Our investment in the company dates back to its Series A round in 2013, and we continued to support its growth through the Series B and D1 rounds.
Founded in 2012, Unisound focuses on building conversational AI products and solutions for everyday life and healthcare-related scenarios, helping users improve operational efficiency and strengthen decision-making capabilities. Its customers include insurance groups and over 100 hospitals.
Duane Kuang, Founding Managing Partner of Qiming Venture Partners, said: "As an early investor in Unisound, we are delighted to witness the company's important leap from technology exploration to IPO. This listing is not only a significant milestone for Unisound's development, but also important progress in China's AI technology moving toward commercialization. We look forward to Unisound taking this listing as a new starting point to continuously deepen technological innovation, accelerate talent development, and demonstrate the hard power of Chinese AI enterprises. Qiming Venture Partners will also continue to patiently support more companies like Unisound that combine technological depth with business vision, constantly exploring and progressing."
Funding News
Biocytogen Completes Nearly RMB 100 Million Series A Round
Qiming Venture Partners Continues Investment
Recently, Biocytogen, a leading enterprise in China's laboratory automation field, announced the completion of a nearly RMB 100 million Series A funding round. Qiming Venture Partners was the exclusive investor in the Pre-A+ round and continued to invest in this round. The injection of funds will strongly promote Biocytogen's acceleration of R&D, global promotion, and widespread adoption of its "intelligent ecosystem for full-process life science automation," empowering broader research and industrial scenarios.
Since its founding in 2014, Biocytogen has been deeply rooted in the life science laboratory automation field, focusing on R&D and production of laboratory automation systems and consumables. With independent innovation in core underlying technologies as its foundation and intelligent manufacturing collaboration across the entire industry chain as its support, the company steadfastly practices its mission as a "popularizer of life science automation." The company has successfully achieved leapfrog development from key technological breakthroughs to the construction of a complete ecosystem, with R&D and production bases in Suzhou, Nanjing, Xiangyang, and Guangzhou.
Dr. Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare, said: "Biocytogen leverages its team advantages in both technology R&D and commercialization capabilities. Through an open ecosystem strategy with laboratory automation as the core lever, the company continuously drives intelligent development in life sciences. We look forward to Biocytogen leading efficiency innovation and industrial upgrading in the life sciences field through standardized solutions."
Major Partnerships
01/
Hesai Technology and Rushi Announce Deepened Strategic Partnership
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) and Rushi, a leader in digital space comprehensive solutions, announced a deepened strategic partnership to jointly launch leading digital space technology solutions. Through integrated hardware-software solutions, the two parties will replicate the physical world and commercial activities within it, adapting to 3D reconstruction needs across different industries and accelerating digital and intelligent transformation across thousands of industries.
In the home decoration design field, the two parties have created an efficient and precise smart home measurement solution through deep integration of Hesai Technology's high-precision LiDAR technology and Rushi's advanced digital space algorithms. This solution enables comprehensive sampling of real geometric dimensions, achieving an average measurement time of four minutes per unit with CAD drawings delivered in 15 minutes, truly realizing low human involvement and fully automatic precise measurement. Currently, KE Holdings' home furnishing brands Beewo and Shengyi have deployed this solution at scale, using digital space solutions to comprehensively cover key nodes in home decoration design, setting a new benchmark for the home decoration industry.
02/
RemeGen and MedSci Healthcare Announce Upgraded Strategic Partnership
Recently, RemeGen and Qiming Venture Partners portfolio company MedSci Healthcare (02415.HK) held a strategic cooperation discussion meeting.
Shuai Wang, CEO of MedSci Healthcare, said: "RemeGen is a benchmark enterprise in China's innovative drug field, performing strongly in global innovative drug R&D competition. The signing of this comprehensive strategic partnership is not only recognition of MedSci Healthcare's past service value, but also a new starting point for both parties to move toward deeper and broader cooperation. Looking ahead, MedSci Healthcare will fully leverage its platform advantages and medical capabilities to jointly accelerate the efficient transformation of innovative achievements into clinical value, assist RemeGen in full lifecycle management of its drugs, promote the improvement of diagnosis and treatment levels in relevant disease areas, and benefit broad patient populations."
03/
YourHealth Medical Joins Ruijin Hospital Shanghai Gastrointestinal Surgery Specialist Alliance
Recently, the unveiling ceremony for "Member Unit of Ruijin Hospital Shanghai Gastrointestinal Surgery Specialist Alliance" was held at Shanghai YourHealth Hospital, a facility under Qiming Venture Partners portfolio company YourHealth Medical, marking YourHealth Medical's official entry into the specialist alliance led by Ruijin Hospital Shanghai.
This marks a new stage in specialist collaboration in gastrointestinal surgery between nationally top-tier public medical resources and international high-quality medical institutions. The partnership aims to leverage Ruijin Hospital's cutting-edge technology and extensive experience to further enhance YourHealth Medical's professional level and service quality in gastrointestinal surgery. Meanwhile, YourHealth Medical's internationalized service model will also inject new vitality into the specialist alliance.
04/
Insilico Medicine Partners with United Arab Emirates University
Advancing Talent Development and Academic Innovation
Qiming Venture Partners portfolio company Insilico Medicine has signed a strategic memorandum of understanding (MoU) with United Arab Emirates University (UAEU), a leading public university and top academic institution in the UAE and the broader Middle East. The partnership aims to foster scientific talent development in the region and jointly advance biotechnology growth and research collaboration in the UAE.
The strategic collaboration between Insilico Medicine and UAEU seeks to build bridges between academia and industry through multi-layered cooperation, including joint research projects, academic exchanges, and hands-on training for students and faculty. The partnership will span several key areas: co-publishing innovative research, hosting expert lectures, organizing educational events such as hackathons and seminars, and offering internship opportunities to qualified UAEU students. Additionally, the collaboration will create career development pathways for UAEU students to join Insilico Medicine, supporting talent growth across the Middle East and bolstering the expansion of the UAE's biotechnology sector.
05/
Shanghai Jiao Tong University Partners with DeepWise to Launch Super Research Platform
Shanghai Jiao Tong University has signed a strategic partnership agreement with Qiming Venture Partners portfolio company DeepWise to advance the deployment and iteration of a super research platform, leveraging the university's AI-X Research Institute.
The super research platform is a full-process, intelligent, large-scale, distributed scientific discovery platform. Built on the "Bohr Research Space Station," it will integrate seamlessly with the university's library, computing center, and analytical testing center — breaking down data silos, reimagining research workflows, and enabling cross-college, cross-platform sharing and elastic allocation of computing power, data, and instrumentation. The platform will create a closed-loop, rapid-iteration system connecting literature review, computational modeling, and experimental testing, lowering barriers to research, accelerating scientific progress, and fostering interdisciplinary innovation. As a new form of research infrastructure for the platform-driven era of science, it will provide one-stop services spanning literature investigation, computational simulation, and experimental testing, aiming to deliver seamless integration across the entire research lifecycle.
Dingke Medical Partners with Mozarc Medical for US Market Strategy
Qiming Venture Partners portfolio company Dingke Medical has announced a US market strategic partnership with Mozarc Medical, a kidney health innovation company, to jointly address clinical challenges faced by dialysis patients — a pressing concern given that more than one in seven American adults lives with kidney disease.
Mozarc Medical will serve as the exclusive promotion and sales partner in the United States for Dingke Medical's DKutting™ high-pressure scoring balloon and DKaptain™ high-pressure balloon catheter, advancing clinical treatment in the hemodialysis access field.
The DKutting™ high-pressure scoring balloon combines directional cutting with high-pressure dilation capabilities. Its proprietary scoring design enables precise treatment of high-resistance calcified lesions while minimizing vascular injury. The DKaptain™ high-pressure balloon catheter is engineered for complex vascular lesions, featuring an ultra-high burst pressure of 26 atm and compatibility with vessel diameters ranging from 3.0mm to 12.0mm, covering the full spectrum of clinical sizing needs.
R&D Progress
Abbisko to Present Latest Clinical Trial Data on Irpagratinib Combined with Atezolizumab for Advanced Hepatocellular Carcinoma
Qiming Venture Partners portfolio company Abbisko (02256.HK) announced it will deliver an oral presentation at the 2025 ESMO Gastrointestinal Oncology Congress (ESMO GI) reporting the latest Phase 2 clinical trial data for its independently developed highly selective small-molecule FGFR4 inhibitor irpagratinib (ABSK-011) in combination with atezolizumab for patients with FGF19-overexpressing advanced hepatocellular carcinoma.
The newly disclosed findings demonstrate that the combination regimen showed favorable safety and significant efficacy in FGF19-overexpressing advanced hepatocellular carcinoma patients, regardless of whether they were treatment-naïve or previously treated. The combination achieved an objective response rate (ORR) of ≥50% and a median progression-free survival (PFS) of ≥7 months. These results not only further validate the substantial potential of this combination therapy in treating FGF19-overexpressing advanced hepatocellular carcinoma, but also offer novel therapeutic perspectives and directions for both patients previously treated with immune checkpoint inhibitors (ICIs) and those without prior ICI exposure — bringing new hope to a broader patient population.
Abbisko Completes First Patient Enrollment in Observational Study for Achondroplasia Treatment
Qiming Venture Partners portfolio company Abbisko (02256.HK) announced that an observational study in children with achondroplasia has completed its first patient enrollment. This study will collect baseline information on pediatric patients to support research on ABSK061, Abbisko's independently developed highly selective small-molecule FGFR2/3 inhibitor for achondroplasia treatment.
In March 2025, ABSK061 received approval from the Center for Drug Evaluation, NMPA (CDE) to conduct clinical studies for treating achondroplasia in children.
ABSK061 is a next-generation oral, highly potent, highly selective small-molecule FGFR2/3 inhibitor independently developed by Abbisko with global intellectual property rights, and the first FGFR2/3-selective inhibitor to enter clinical trials worldwide. First-generation pan-FGFR inhibitors have demonstrated clinical efficacy across multiple tumor types harboring FGFR2/3 alterations and have gradually gained regulatory approvals globally, but their therapeutic window and efficacy are both constrained by FGFR1 inhibition-related side effects. By reducing FGFR1 inhibition while maintaining high activity against FGFR2/3, ABSK061 as a second-generation FGFR inhibitor holds promise for achieving a superior safety profile and clinical efficacy.
MediLink Therapeutics' YL201 Receives FDA Breakthrough Therapy Designation
Qiming Venture Partners portfolio company MediLink Therapeutics announced that YL201 has been granted Breakthrough Therapy Designation by the FDA for the treatment of small cell lung cancer (SCLC).
YL201 is a B7H3-targeting antibody-drug conjugate (ADC) developed based on MediLink Therapeutics' proprietary TMALIN® technology platform. The YL201 program is currently advancing multiple clinical studies globally. Its small cell lung cancer and nasopharyngeal carcinoma indications have entered Phase 3 clinical trials in China. YL201 is also actively pursuing multiple monotherapy and combination trials to explore its therapeutic potential across various solid tumor types.
Product Launches
Xiaomi Hosts "Human x Car x Home" Ecosystem Launch Event
Unveils Multiple New Products
Qiming Venture Partners portfolio company Xiaomi (01810.HK) recently held its "Human x Car x Home" ecosystem launch event, officially releasing the Xiaomi Open-Ear Headphones Pro, the Xiaomi YU7, the Xiaomi MIX Flip 2, and the Xiaomi AI Glasses.
Among these, the Xiaomi Open-Ear Headphones Pro features an ultra-compact earbud design and slim ear hooks that are particularly friendly to glasses wearers. The product also adopts an ergonomic three-point support structure that distributes the already lightweight device's weight across three contact points, and has earned TÜV SÜD's "High Wearing Comfort Certification for Headphones." The Xiaomi Open-Ear Headphones Pro is the first in the industry to feature an open-ear five-driver acoustic system, with dedicated bass units and treble modules each handling their respective frequency ranges. Addressing a common concern with open-ear headphones — sound leakage — the device incorporates Xiaomi's self-developed independent anti-leakage system, certified by the China Academy of Metrology.
UBTECH Releases Commercial Humanoid Robot
Smart Exhibition Solution
Qiming Venture Partners portfolio company UBTECH (09880.HK) has launched a commercial humanoid robot smart exhibition solution, redefining standards for guided tour services. The solution breaks through the spatial and temporal limitations of traditional guided tours, achieving deep integration of "technology + humanities" through Embodied Artificial Intelligence technology, and building next-generation intelligent service infrastructure for exhibition halls worldwide.
Centered on the Walker C — a new-generation, fully electric, humanoid-running, full-size commercial humanoid robot — the solution integrates a self-developed Embodied Artificial Intelligence interaction large model, semantic V-SLAM navigation, and bionic joint control algorithms to build a full-stack guided tour capability combining "listening, speaking, and moving." Applicable to exhibition halls, shopping centers, transportation hubs, and other scenarios, the solution enhances visitor experience, brand reach, and operational efficiency through reception, intelligent guided tours, and emotive interaction, setting a new benchmark for warm, digitalized guided tour experiences.
Insta360 Releases AI Smartphone Gimbal Flow 2
Qiming Venture Partners portfolio company Insta360 (688775.SH) has released the AI smartphone gimbal Flow 2, positioned as "the first Vlog companion for young people."
Flow 2 covers many features from the flagship Flow 2 Pro, equipped with Insta360's self-developed AI Deep Track 4.0 technology, enabling dynamic long-zoom tracking, intelligent multi-person tracking, and intelligent aesthetic composition. The body features a three-axis stabilization system and compact, portable integrated design with a built-in selfie stick and tripod, allowing users to start shooting in one step.
04/
Insilico Medicine Releases Chemical Foundation Model Nach01
Qiming Venture Partners portfolio company Insilico Medicine participated in AWS Summit China, debuting its chemical foundation model Nach01, now available on AWS Marketplace, and showcasing its Pharma.AI drug discovery solution at the "Building Digital Life Sciences" exhibition zone.
The Nach01 released on AWS Marketplace this time by Insilico Medicine builds upon and extends the capabilities of Nach0 and Nach0-pc, achieving an innovative fusion of natural language processing and advanced chemical intelligence. Nach01 features 2D and 3D information prediction capabilities, with application scenarios covering over a hundred differentiated tasks such as synthetic route prediction and ADMET property prediction. Additionally, Nach01 supports training, fine-tuning, and inference based on users' own data. Currently, users can access Nach01 securely and scalably through AWS Marketplace, and can also achieve more streamlined and efficient deployment through Amazon SageMaker.
Technology & Capabilities
01/
Hesai Technology ATX Receives ISO 26262 ASIL B Functional Safety Product Certification
Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) announced that its ATX — an automotive-grade, compact, ultra-high-definition long-range LiDAR — has officially passed the ISO 26262 ASIL B functional safety product certification issued by international authoritative testing and certification body SGS-TÜV, providing more robust and higher-specification safety assurance for the large-scale mass production of advanced driver assistance functions.
The Hesai ATX follows the Pandar128, QT128, and AT128 as the fourth LiDAR product to pass this certification, strengthening Hesai Technology's "safety iron triangle" covering functional safety, cybersecurity, and safety of the intended functionality processes, and further solidifying its leading position in the industry. To date, Hesai Technology has become the company with the most ISO 26262 functional safety product certifications in the industry.
02/
Infinigence AI Founder Yu Wang Delivers Keynote at Inaugural ModelScope Developer Conference
At the inaugural ModelScope Developer Conference, Yu Wang — professor and department chair of the Department of Electronic Engineering at Tsinghua University, and founder of Qiming Venture Partners portfolio company Infinigence AI — delivered a keynote speech titled "The Next Stop for Edge Intelligence: Hardware Innovation and Technical Breakthroughs and Challenges in On-Device AI." Taking hardware-software co-design as the core methodology and Embodied Artificial Intelligence as the future anchor point, the speech focused on the challenges and solutions for deploying large models on edge devices, systematically presenting the full landscape of on-device AI from challenges to technical breakthroughs.
Professor Wang proposed a hardware-software co-design path forward. At the model level, by integrating computing power, data, and developer community resources, efficient small models can be built. For example, Megrez-3B-Omni — an on-device full-modal large model jointly launched by Infinigence AI and ModelScope — deeply integrated hardware-software co-optimization during development, achieving an excellent balance between inference speed and accuracy, and delivering best-in-class inference performance at the time across multimodal tasks spanning text, image, and audio. At the software level, inference optimization software for general scenarios needs to be developed. Taking Infinigence AI's Mizar intelligent terminal acceleration inference engine as an example, this engine is an independently controllable large model hardware-software adaptation platform built for PCs, computing boxes, and other intelligent terminals, achieving substantial inference speed improvements across multiple application scenarios while significantly reducing power consumption and memory footprint — truly transforming AI capabilities into the intrinsic DNA of terminal devices. At the hardware level, customized accelerators and novel devices/computing paradigms are needed to break through traditional architecture limitations and significantly improve energy efficiency and processing speed. For example, Infinigence AI's self-developed large-model-specific inference processor LPU IP supports multimodal large models including text-to-text, text-to-image, and text-to-video, supports 3D-stacked DRAM, and achieves computing power and energy efficiency surpassing high-end process/high-computing-power GPUs on low-end process/low-computing-power FPGAs. Through "algorithm-software-architecture-process" co-optimization, substantially outperforming mainstream chips domestically and internationally, on-device large model performance and energy efficiency are greatly enhanced.
03/
Mech-Mind Robotics Appears at automatica Munich
Recently, automatica 2025 — the International Trade Fair for Robotics and Automation — was held at the Munich Exhibition Center in Germany. Qiming Venture Partners portfolio company Mech-Mind Robotics made its third appearance at the show, demonstrating several industry-leading Embodied AI technologies including registration-free high-speed object grasping and ultra-long-distance imaging, as well as practical applications of its self-developed robot AI brain and 3D vision systems across industrial manufacturing, logistics handling, and industrial quality inspection.
Germany was one of Mech-Mind Robotics' earliest international markets. In 2019, the company established a subsidiary in Munich to build out a comprehensive customer service system covering product, sales, and delivery. To better serve local and European customers, Mech-Mind Robotics' German intelligent showroom officially opened this year. This smart space integrates display, training, warehousing, and meeting functions, further enhancing local technical support capabilities and customer service experience while accelerating the scaled deployment of AI + robotics technology across more industries and scenarios.
04/
DeepWay Delivers First Batch of 10 New Energy Heavy Trucks to Yunnan Xinyuan Lvneng
Recently, Qiming Venture Partners portfolio company DeepWay successfully delivered its first batch of 10 new energy heavy trucks to Yunnan Xinyuan Lvneng. This delivery marks the official launch of China's first inter-provincial, cross-border new energy heavy truck transport corridor.
As a critical link in trunk line transportation, vehicle performance directly impacts operational efficiency and overall logistics performance. The 10 DeepWay intelligent new energy heavy trucks delivered feature four core advantages: high compatibility, ultra-fast battery swapping, extended range, and intelligent management. The vehicles enable 3-5 minute battery swaps, reduce transport costs by over 20% compared to traditional fuel vehicles, and improve overall efficiency by 30% — delivering substantial economic benefits.
05/
Superhexa Appears at Shenzhen International Optical Fair and Partners with Asian Optical
Recently, Qiming Venture Partners portfolio company Superhexa showcased its self-owned brand Jiehuan AI audio glasses at the 2025 Shenzhen International Optical Fair, attracting numerous professional visitors and testers with its product philosophy of "good-looking, comfortable, smart, and easy to use."
Jiehuan also announced a partnership with Asian Optical to help create China's first AI smart product experiential shopping center — "101 SmartHub AI Collection Space." Consumers will be able to deeply experience the intelligent, efficient, and convenient new lifestyle enabled by AI smart glasses.
06/
Gan & Lee Pharmaceuticals Showcases Full Range of Insulin Products and Delivery Devices at CPHI China 2025
At the 23rd World Pharmaceutical Raw Materials China Exhibition (CPHI China 2025), Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) adopted a dual-zone exhibition model combining product display and business negotiation, comprehensively showcasing its full range of insulin products and accompanying delivery devices, fully demonstrating to the industry Gan & Lee's competitive advantages across the entire industrial chain from innovative R&D to global layout.
Kai Du, Executive Vice President and Chief Commercial Officer of Gan & Lee Pharmaceuticals, stated: "We are committed to providing better and more convenient treatment options for diabetes patients worldwide through continuous R&D innovation. This concentrated showcase of our product portfolio and in-depth engagement with international business fully reflects our innovation capabilities and global strategic deployment. We believe that, relying on our deep expertise in the diabetes field, rich product pipeline, and global partnership network, Gan & Lee is confident in playing a more important role in the global diabetes treatment market and benefiting more patients."
07/
Fushoukang Participates in Developing China's First National Standard for Brand Value Evaluation in Elderly Care Services
Recently, China's State Administration for Market Regulation and Standardization Administration issued and implemented the national standard Brand Value Evaluation — Elderly Care Services (GB/T 45491-2025), China's first national standard for brand value evaluation in the elderly care services industry. Qiming Venture Partners portfolio company Fushoukang, as one of the drafting units, fully participated in the development of this standard, contributing key technical expertise to the industry's standardization and high-quality development.
The national standard Brand Value Evaluation — Elderly Care Services (GB/T 45491-2025) refines 46 indicators for measuring brand strength in China's elderly care services industry across five dimensions: tangible elements, quality elements, innovation elements, service elements, and intangible elements. It proposes models, methods, and processes for conducting brand value evaluation in elderly care services, providing guidance for scientifically standardized brand value evaluation. Implementation of this standard will help lead elderly care service institutions to continuously improve service quality, cultivate service brands, and better meet the growing multi-level, high-quality elderly care needs of older adults.
08/
NOPRINT CEO Xi Yang Delivers Keynote at 2025 Chinese Society of Biomedical Engineering Conference and Innovative Medical Summit
At the 2025 Chinese Society of Biomedical Engineering Conference and Innovative Medical Summit, Xi Yang, CEO of Qiming Venture Partners portfolio company NOPRINT, delivered a keynote speech titled "3D Printing Technology Based on Bioregenerative Materials: Present and Future Clinical Applications."
She noted that the core advantage of bioprinting technology lies in its ability to precisely simulate tissue microenvironments and achieve "physiological regeneration." Compared with traditional therapies, bioprinting can address limitations in autologous transplant sources, immune rejection, and secondary surgeries. For example, NOPRINT's developed "NPPM regenerative bone graft" achieves rapid bone ingrowth and complete degradation through biomimetic design and degradable materials, significantly improving clinical outcomes.
She called for strengthened industry-university-research collaboration to accelerate technology transfer and jointly promote innovative development in the healthcare industry. As an industry leader, NOPRINT will continue exploring clinical applications of bioprinting to contribute to human health.
09/
Shulan (Boao) Hospital (Pilot Operation) Under Shulan Health Introduces Intelligent Cochlear Implant System
At the "Future Hearing, Smart Choice Today" Cochlear Nexa new technology launch event, the Cochlear Nexa system completed its first global applications at Shulan (Boao) Hospital (pilot operation) under Qiming Venture Partners portfolio company Shulan Health.
Shulan Health has consistently been at the forefront of introducing the latest global medical advances, and has successfully performed multiple特许 cochlear implant surgeries. This pioneering introduction of Cochlear's intelligent cochlear implant system Nexa, and achievement of first global use, represents yet another important milestone in Shulan Health's journey of realizing特许 pharmaceuticals and medical devices, medical technology, and innovative transformation — contributing to the accelerated convergence, efficient implementation, and widespread application of world-class medical resources.
Corporate Honors
01/ Four Qiming Venture Partners Portfolio Companies Named to World Artificial Intelligence Conference SAIL Award TOP30
Recently, the World Artificial Intelligence Conference · SAIL (Super AI Leader) Award TOP30 list was released. The SAIL Award, as a high-specification, international honor in the world artificial intelligence field, adheres to the philosophy of "pursuing excellence, leading the future" to discover globally leading AI projects with high recognition and reputation that enhance human welfare, aiming to inspire technological breakthroughs, application innovation, and governance exploration while leading intelligent transformation.
Qiming Venture Partners portfolio companies Xiaomi (01810.HK), Tianwu Technology, Biren Technology, and Galaxy Universal were named to the SAIL Award TOP30 list.
02/ Three Qiming Venture Partners Portfolio Companies Named to 2025
Kantar BrandZ Top 50 Chinese Global Brands
Kantar and Google recently unveiled the 2025 Kantar BrandZ Top 50 Chinese Global Brands. The list not only clearly demonstrates the rising global influence of Chinese brands, but also provides an authoritative lens for understanding competitive dynamics in international markets.
Qiming Venture Partners portfolio companies Xiaomi (01810.HK), Insta360 (688775.SH), and Roborock (688169.SH) made the list.
03/
Insilico Medicine Ranks 9th Among Chinese Biotech Institutions on 2025 Nature Index Research Leaders
The 2025 Nature Index Research Leaders was recently released. Thanks to sustained research breakthroughs at the intersection of biotechnology, AI, and automation, Qiming Venture Partners portfolio company Insilico Medicine ranked 42nd globally among biotech institutions and 9th among Chinese biotech institutions.
During the measurement period, Insilico Medicine published 55 academic papers and reports. Major findings published in leading journals including Nature Biotechnology were the primary drivers of its ranking improvement. Among them, a March 2024 paper comprehensively detailed the complete preclinical R&D journey of Rentosertib (ISM001-055) — the company's first-in-class TNIK inhibitor discovered and designed by generative AI — from target identification to clinical candidate nomination, highlighting the cost and efficiency advantages of AI-driven drug discovery. A December 2024 study detailed the design and optimization of the novel gut-restricted PHD inhibitor ISM5411 through the integrated generative chemistry engine Chemistry42, demonstrating the significant potential of cutting-edge AI technology to accelerate solutions for unmet clinical needs.
Past Highlights
Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Vol. 22, 2025 Qiming Stars | 3 Qiming Venture Partners Portfolio Companies Named to 2025 Kantar BrandZ Top 50 Chinese Global Brands
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. More than 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.